Targeting oncomiRs such as miR-21 and miR-181-b, and lack of PDCD4 in colitis and CAC mice models have been associated with enhanced IL-6 production, intensified activity of STAT3 signaling pathway, enhanced colitis and proliferation of tumor cells [142, 143]. Here, IL6 is linked to neoplasm.